Successful management of Netherton syndrome using IVIG and dupilumab: A case report
- PMID: 40607310
- PMCID: PMC12221484
- DOI: 10.1016/j.jacig.2025.100508
Successful management of Netherton syndrome using IVIG and dupilumab: A case report
Abstract
Netherton syndrome (NS) is a rare autosomal recessive genodermatosis caused by pathogenic mutations in the serine protease inhibitor Kazal-type 5 (SPINK5) gene, leading to impaired skin barrier function and immune dysregulation. It is characterized by congenital ichthyosis, trichorrhexis invaginata, and severe atopy. Herein, we present the case of a young boy with NS, confirmed by genetic analysis revealing a homozygous splice site mutation in SPINK5 (c.1302+5G>C). The patient was treated with intravenous immunoglobulin due to frequent infections that required multiple hospital admissions. When he was 6 years old, dupilumab was added to reduce skin inflammation and improve skin barrier function before food reintroduction. He demonstrated substantial clinical benefits, with marked relief from pruritus resulting in better quality of life. Additionally, he exhibited notable hair growth. Serologically, total his serum IgE levels decreased from 1078 IU/mL to 55.8 IU/mL following dupilumab therapy. This case highlights the potential benefits of an integrated therapeutic approach in management of this challenging condition.
Keywords: IVIG; Netherton syndrome; SPINK5; bamboo hair; dupilumab; food allergy; trichorrhexis invaginata.
© 2025 The Author(s).
Conflict of interest statement
Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.
Figures

Similar articles
-
Systemic treatments for eczema: a network meta-analysis.Cochrane Database Syst Rev. 2020 Sep 14;9(9):CD013206. doi: 10.1002/14651858.CD013206.pub2. Cochrane Database Syst Rev. 2020. PMID: 32927498 Free PMC article.
-
Netherton Syndrome Perspectives.Curr Pediatr Rev. 2025 Jun 19. doi: 10.2174/0115733963361849250611072347. Online ahead of print. Curr Pediatr Rev. 2025. PMID: 40551686
-
Dominant dystrophic epidermolysis bullosa is associated with glycolytically active GATA3+ T helper 2 cells which may contribute to pruritus in lesional skin.Br J Dermatol. 2024 Jul 16;191(2):252-260. doi: 10.1093/bjd/ljae110. Br J Dermatol. 2024. PMID: 38477474
-
Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome.Cochrane Database Syst Rev. 2022 Mar 11;3(3):CD013130. doi: 10.1002/14651858.CD013130.pub2. Cochrane Database Syst Rev. 2022. PMID: 35274741 Free PMC article.
-
Dupilumab in the treatment of genodermatosis: A systematic review.J Dtsch Dermatol Ges. 2023 Jan;21(1):7-17. doi: 10.1111/ddg.14924. Epub 2023 Jan 19. J Dtsch Dermatol Ges. 2023. PMID: 36657040
References
-
- Chavanas S., Bodemer C., Rochat A., Hamel-Teillac D., Ali M., Irvine A.D., et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet. 2000;25 - PubMed
-
- Chiticariu E., Hohl D. Netherton syndrome: insights into pathogenesis and clinical implications. J Invest Dermatol. 2020;140:1129–1130. - PubMed
-
- Guerra L., Fortugno P., Pedicelli C., Mazzanti C., Proto V., Zambruno G., Castiglia D. Ichthyosis linearis circumflexa as the only clinical manifestation of Netherton syndrome. Acta Derm Venereol. 2015;95:720–724. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous